<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01439893</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-01-303</org_study_id>
    <nct_id>NCT01439893</nct_id>
  </id_info>
  <brief_title>Study of Efficacy on Cardiac Remodeling of Recombinant Human Neuregulin-1 in Stable Chronic Systolic Heart Failure Patients</brief_title>
  <official_title>A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zensun Sci. &amp; Tech. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zensun Sci. &amp; Tech. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind , placebo parallel controlled, standard&#xD;
      therapy based phase III clinical trial, to evaluate the efficacy of recombinant human&#xD;
      neuregulin-1 on cardiac remodeling, as well as safety in patients with chronic heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RhNRG-1(recombinant human neuregulin-1)directly works on the cardiomyocytes and restored the&#xD;
      normal structure and function of it.Both the preclinical trial and phase II clinical trail&#xD;
      have confirmed that rhNRG-1 effectively improved the heart function, and is tolerated in the&#xD;
      effective dosage groups. The aim of this phase III trial is to further confirm in large&#xD;
      population that rhRNG-1 administration can effectively improve the cardiac remodeling and is&#xD;
      tolerated in patients with chronic heart failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor has designed another study with different endpoint to replace the current study&#xD;
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal pro-BNP</measure>
    <time_frame>30 days and 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Chronic Systolic Heart Failure</condition>
  <arm_group>
    <arm_group_label>rhNRG-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Excipient placebo in addition to basic therapy of chronic heart failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNRG-1</intervention_name>
    <description>day1~day10:0.6ug/kg/day,10hours per day for vein infusion</description>
    <arm_group_label>rhNRG-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>day1~day10:0.6ug/kg/day,10hours per day for vein infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18 and 75, both sex.&#xD;
&#xD;
          2. Left ventricular ejection fraction (LVEF)≤40% (ECHO).&#xD;
&#xD;
          3. NYNA functional class II~III.&#xD;
&#xD;
          4. Definitely diagnosed with chronic systolic heart failure (including medical records,&#xD;
             symptoms and physical signs)and clinical symptom is steadily in the latest 1 month.&#xD;
&#xD;
          5. Receiving standard basic treatment of heart failure, has reached the objective dosage&#xD;
             or the highest tolerated dosage for at least 1 month, or the dosage has not been&#xD;
             changed for at least 1 month.&#xD;
&#xD;
          6. Capable of signing the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with atrial fibrillation.&#xD;
&#xD;
          2. Patients with a pacemaker.&#xD;
&#xD;
          3. Patient with a metallic implant.&#xD;
&#xD;
          4. Patient with Claustrophobia.&#xD;
&#xD;
          5. Patients with acute myocardial infarction, Hypertrophic cardiomyopathy, constrictive&#xD;
             pericarditis, significant valvular pathological change or congenital heart diseases,&#xD;
             severe pulmonary artery hypertension.&#xD;
&#xD;
          6. Ischemic heart failure without recanalization or with recanalization in recent six&#xD;
             months.&#xD;
&#xD;
          7. Cardiac surgery or cerebrovascular accident within recent six months.&#xD;
&#xD;
          8. Preparing for heart transplantation or has received CRT treatment.&#xD;
&#xD;
          9. Serious hepatic or renal dysfunction caused by organic pathological changes&#xD;
             (Cr&gt;2.0mg/dl, AST or ALT 5 times above the normal upper limit).&#xD;
&#xD;
         10. Patients need mechanical ventilation.&#xD;
&#xD;
         11. Systolic blood pressure &lt;90mmHg or &gt;160mmHg.&#xD;
&#xD;
         12. Patients with acute hemodynamic disorder or decompensation in the last 1 month.&#xD;
&#xD;
         13. Serious ventricular arrhythmia (multi-morphological premature ventricular contraction,&#xD;
             frequent paroxysmal ventricular tachycardia).&#xD;
&#xD;
         14. Serum potassium &lt;3.2 mmol/L or &gt;5.5 mmol/L.&#xD;
&#xD;
         15. Pregnant or plan to pregnant.&#xD;
&#xD;
         16. Unmarried or married but not procreated women at child-bearing age.&#xD;
&#xD;
         17. Subject with a life expectancy less than 6 months as assessed by the investigator.&#xD;
&#xD;
         18. Patients who participated in any clinical trial in the recent three months.&#xD;
&#xD;
         19. History of any malignancy or suffering from cancer,or biopsy proven pre-malignant&#xD;
             condition (eg DICS or cervical atypia).&#xD;
&#xD;
         20. Evidence (physical examination,CXR,ECHO or other tests) shows some active malignancy&#xD;
             or adenoidal hypertrophy or neoplasm has effect on heart function or endocrine system,&#xD;
             eg pheochromocytoma or hyperthyroidism.&#xD;
&#xD;
         21. Judging by the investigator, the patients could not complete the study or adhere to&#xD;
             the study requirements (due to the management reasons or others).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Runlin Gao, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Affiliate of Capital University of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Chao Yang Hospital, Affiliate of Capital University of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Chinese People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>September 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2011</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic heart failure</keyword>
  <keyword>rhNRG-1</keyword>
  <keyword>Cardiac remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

